Novo Nordisk inks pact with Kallyope to tackle obesity & diabetes
Category: #health  By Saipriya Iyer  Date: 2018-06-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novo Nordisk inks pact with Kallyope to tackle obesity & diabetes

Kallyope Inc., a platform biotech company, and Novo Nordisk A/S, a Denmark based healthcare firm, have declared that they have both signed an option agreement for jointly carrying out research programs to discover new peptide treatments for diabetes & obesity.

As per the terms & conditions stated in the deal, Kallyope will get an upfront fee & research support for the jointly conducted activities. Novo Nordisk has been offered an option to license the rights to develop and commercialize six products in the collaboration, cite sources.

On the other hand, Kallyope is likely to get a license fee if Novo exercises the option for a therapeutic that is discovered and approved in the joint plan. Furthermore, the biotech firm is expected to fetch royalties on the global sales of licensed products.

Reportedly, Kallyope & Novo, under a joint research plan, will work on in vivo and in vito studies in order to legalize myriad drug candidates. Post validation & option exercise, Novo Nordisk is anticipated to further perform pre-clinical & clinical trials and undertake responsibility for manufacturing and commercializing products as well.

Nancy Thornberry, the CEO of Kallyope, has stated that integrating Novo Nordisk’s capabilities with Kallyope’s unique platform will support latter’s small molecule focus. She further highlighted on Novo Nordisk’s expertise in peptide therapeutics discovery & development and appreciated the firm’s commitment & leading role for effectively treating obesity & diabetes.

Marcus Schindler, Senior VP of Global Drug Discovery at Novo Nordisk, has commented that Kallyope has created a unique platform and is led by a strong team. He further stated that Novo holds a lot of experience in disease biology as well as peptide & peptidomics production and the projects that both the firms are expected to jointly work on will make a quite some difference in the lives of diabetics and obese patients.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...